Oculis Advances Privosegtor to Registrational Program After FDA Meeting
Ticker: OCSAW · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1953530
| Field | Detail |
|---|---|
| Company | Oculis Holding Ag (OCSAW) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $182 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-development, fda, clinical-trials
TL;DR
Oculis' Privosegtor gets FDA green light for registrational trials in neuro-ophthalmology.
AI Summary
Oculis Holding AG announced on October 6, 2025, that its drug candidate, Privosegtor (OCS-05), will advance into a registrational program for neuro-ophthalmology indications. This decision follows a positive meeting with the U.S. Food and Drug Administration (FDA). Privosegtor is a novel peptoid small molecule designed to be a first-in-class neuroprotective therapy for acute optic nerve damage.
Why It Matters
This advancement signifies a critical step towards potentially bringing a new treatment to patients suffering from acute optic nerve damage, a condition with limited therapeutic options.
Risk Assessment
Risk Level: medium — Advancing to a registrational program is a significant milestone, but drug development is inherently risky, with many candidates failing in later-stage trials.
Key Players & Entities
- Oculis Holding AG (company) — Registrant
- Privosegtor (drug_candidate) — OCS-05
- OCS-05 (drug_candidate) — Privosegtor
- U.S. Food and Drug Administration (company) — FDA
- FDA (company) — U.S. Food and Drug Administration
- October 6, 2025 (date) — Announcement date
FAQ
What is the primary indication Oculis Holding AG is targeting with Privosegtor?
Oculis Holding AG is targeting neuro-ophthalmology indications, specifically for acute optic nerve damage, with its drug candidate Privosegtor.
What is the significance of the meeting with the FDA?
The meeting with the FDA was positive and led to the decision to advance Privosegtor into a registrational program.
What type of molecule is Privosegtor?
Privosegtor is described as a new peptoid small molecule candidate.
What is the potential therapeutic benefit of Privosegtor?
Privosegtor has the potential to become the first neuroprotective therapy for acute optic nerve damage.
When was this information reported?
This information was reported in a Form 6-K filed on October 6, 2025.
Filing Stats: 929 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2025-10-06 16:40:07
Key Financial Figures
- $182 million — hort-term investments was approximately $182 million. Oculis' cash runway is expected to be
Filing Documents
- d891485d6k.htm (6-K) — 19KB
- d891485dex991.htm (EX-99.1) — 29KB
- d891485dex992.htm (EX-99.2) — 20KB
- g891485ex99_2s10g1.jpg (GRAPHIC) — 90KB
- g891485ex99_2s11g1.jpg (GRAPHIC) — 137KB
- g891485ex99_2s12g1.jpg (GRAPHIC) — 88KB
- g891485ex99_2s13g1.jpg (GRAPHIC) — 101KB
- g891485ex99_2s14g1.jpg (GRAPHIC) — 100KB
- g891485ex99_2s15g1.jpg (GRAPHIC) — 77KB
- g891485ex99_2s1g1.jpg (GRAPHIC) — 75KB
- g891485ex99_2s2g1.jpg (GRAPHIC) — 174KB
- g891485ex99_2s3g1.jpg (GRAPHIC) — 36KB
- g891485ex99_2s4g1.jpg (GRAPHIC) — 114KB
- g891485ex99_2s5g1.jpg (GRAPHIC) — 112KB
- g891485ex99_2s6g1.jpg (GRAPHIC) — 63KB
- g891485ex99_2s7g1.jpg (GRAPHIC) — 111KB
- g891485ex99_2s8g1.jpg (GRAPHIC) — 101KB
- g891485ex99_2s9g1.jpg (GRAPHIC) — 138KB
- g891485img001.jpg (GRAPHIC) — 9KB
- 0001193125-25-231973.txt ( ) — 2174KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OCULIS HOLDING AG Date: October 6, 2025 By: /s/ Sylvia Cheung Sylvia Cheung Chief Financial Officer